Baseline characteristics of patients at the time of initial administration of immune checkpoint inhibitor
| . | Lung cancer and PD1i . | Malignant melanoma and CTLA-4i . | Malignant melanoma and PD1i . |
|---|---|---|---|
| N | 743 | 212 | 145 |
| Age, median (p25–p75) | 67 (60–72) | 64 (54–70) | 62 (51–74) |
| Men, n (%) | 391 (52.6) | 123 (58.0) | 86 (59.3) |
| Comorbidity at ICI administration, n (%) | |||
| Myocardial infarction | 40 (5.4) | 10 (4.7) | <3 |
| Heart failure | 29 (3.9) | 5 (2.4) | <3 |
| Myocarditis | 14 (1.9) | <3 | <3 |
| Arrhythmia | 104 (14.0) | 20 (9.4) | 13 (9.0) |
| Peripheral arterial disease | 14 (1.9) | 3 (1.4) | <3 |
| Diabetes mellitus | 91 (12.2) | 22 (10.4) | 16 (11.0) |
| Hypertension | 189 (25.4) | 53 (25.0) | 39 (26.9) |
| Chronic kidney disease | 17 (2.3) | 3 (1.4) | 3 (2.1) |
| Alcohol abuse | 11 (1.5) | 12 (5.7) | 4 (2.8) |
| Chronic liver disease | 4 (0.5) | <3 | 5 (3.4) |
| Chronic obstructive pulmonary disease | 102 (13.7) | 7 (3.3) | <3 |
| Pharmacotherapy at ICI administration, n (%) | |||
| Calcium channel blockers | 114 (15.3) | 33 (15.6) | 24 (16.6) |
| Beta blockers | 150 (20.2) | 38 (17.9) | 13 (9.0) |
| Non loop diuretics | 145 (19.5) | 39 (18.4) | 38 (26.2) |
| Loop diuretics | 71 (9.6) | 12 (5.7) | 7 (4.8) |
| RAS-inhibitors | 189 (25.4) | 57 (26.9) | 41 (28.3) |
| Vitamin K antagonists | 33 (4.4) | 4 (1.9) | 3 (2.1) |
| Non vitamin K antagonists | 40 (5.4) | 3 (1.4) | 4 (2.8) |
| ADP-inhibitors | 42 (5.7) | 13 (6.1) | 8 (5.5) |
| Aspirin | 147 (19.8) | 25 (11.8) | 15 (10.3) |
| Statins | 194 (26.1) | 45 (21.2) | 23 (15.9) |
| . | Lung cancer and PD1i . | Malignant melanoma and CTLA-4i . | Malignant melanoma and PD1i . |
|---|---|---|---|
| N | 743 | 212 | 145 |
| Age, median (p25–p75) | 67 (60–72) | 64 (54–70) | 62 (51–74) |
| Men, n (%) | 391 (52.6) | 123 (58.0) | 86 (59.3) |
| Comorbidity at ICI administration, n (%) | |||
| Myocardial infarction | 40 (5.4) | 10 (4.7) | <3 |
| Heart failure | 29 (3.9) | 5 (2.4) | <3 |
| Myocarditis | 14 (1.9) | <3 | <3 |
| Arrhythmia | 104 (14.0) | 20 (9.4) | 13 (9.0) |
| Peripheral arterial disease | 14 (1.9) | 3 (1.4) | <3 |
| Diabetes mellitus | 91 (12.2) | 22 (10.4) | 16 (11.0) |
| Hypertension | 189 (25.4) | 53 (25.0) | 39 (26.9) |
| Chronic kidney disease | 17 (2.3) | 3 (1.4) | 3 (2.1) |
| Alcohol abuse | 11 (1.5) | 12 (5.7) | 4 (2.8) |
| Chronic liver disease | 4 (0.5) | <3 | 5 (3.4) |
| Chronic obstructive pulmonary disease | 102 (13.7) | 7 (3.3) | <3 |
| Pharmacotherapy at ICI administration, n (%) | |||
| Calcium channel blockers | 114 (15.3) | 33 (15.6) | 24 (16.6) |
| Beta blockers | 150 (20.2) | 38 (17.9) | 13 (9.0) |
| Non loop diuretics | 145 (19.5) | 39 (18.4) | 38 (26.2) |
| Loop diuretics | 71 (9.6) | 12 (5.7) | 7 (4.8) |
| RAS-inhibitors | 189 (25.4) | 57 (26.9) | 41 (28.3) |
| Vitamin K antagonists | 33 (4.4) | 4 (1.9) | 3 (2.1) |
| Non vitamin K antagonists | 40 (5.4) | 3 (1.4) | 4 (2.8) |
| ADP-inhibitors | 42 (5.7) | 13 (6.1) | 8 (5.5) |
| Aspirin | 147 (19.8) | 25 (11.8) | 15 (10.3) |
| Statins | 194 (26.1) | 45 (21.2) | 23 (15.9) |
ADP, adenosine diphosphate; CTLA-4i, cytotoxic T-lymphocyte-associated protein-4 inhibitor, PD1i, programmed cell death 1 inhibitor; RAS, renin-angiotensin system.
Baseline characteristics of patients at the time of initial administration of immune checkpoint inhibitor
| . | Lung cancer and PD1i . | Malignant melanoma and CTLA-4i . | Malignant melanoma and PD1i . |
|---|---|---|---|
| N | 743 | 212 | 145 |
| Age, median (p25–p75) | 67 (60–72) | 64 (54–70) | 62 (51–74) |
| Men, n (%) | 391 (52.6) | 123 (58.0) | 86 (59.3) |
| Comorbidity at ICI administration, n (%) | |||
| Myocardial infarction | 40 (5.4) | 10 (4.7) | <3 |
| Heart failure | 29 (3.9) | 5 (2.4) | <3 |
| Myocarditis | 14 (1.9) | <3 | <3 |
| Arrhythmia | 104 (14.0) | 20 (9.4) | 13 (9.0) |
| Peripheral arterial disease | 14 (1.9) | 3 (1.4) | <3 |
| Diabetes mellitus | 91 (12.2) | 22 (10.4) | 16 (11.0) |
| Hypertension | 189 (25.4) | 53 (25.0) | 39 (26.9) |
| Chronic kidney disease | 17 (2.3) | 3 (1.4) | 3 (2.1) |
| Alcohol abuse | 11 (1.5) | 12 (5.7) | 4 (2.8) |
| Chronic liver disease | 4 (0.5) | <3 | 5 (3.4) |
| Chronic obstructive pulmonary disease | 102 (13.7) | 7 (3.3) | <3 |
| Pharmacotherapy at ICI administration, n (%) | |||
| Calcium channel blockers | 114 (15.3) | 33 (15.6) | 24 (16.6) |
| Beta blockers | 150 (20.2) | 38 (17.9) | 13 (9.0) |
| Non loop diuretics | 145 (19.5) | 39 (18.4) | 38 (26.2) |
| Loop diuretics | 71 (9.6) | 12 (5.7) | 7 (4.8) |
| RAS-inhibitors | 189 (25.4) | 57 (26.9) | 41 (28.3) |
| Vitamin K antagonists | 33 (4.4) | 4 (1.9) | 3 (2.1) |
| Non vitamin K antagonists | 40 (5.4) | 3 (1.4) | 4 (2.8) |
| ADP-inhibitors | 42 (5.7) | 13 (6.1) | 8 (5.5) |
| Aspirin | 147 (19.8) | 25 (11.8) | 15 (10.3) |
| Statins | 194 (26.1) | 45 (21.2) | 23 (15.9) |
| . | Lung cancer and PD1i . | Malignant melanoma and CTLA-4i . | Malignant melanoma and PD1i . |
|---|---|---|---|
| N | 743 | 212 | 145 |
| Age, median (p25–p75) | 67 (60–72) | 64 (54–70) | 62 (51–74) |
| Men, n (%) | 391 (52.6) | 123 (58.0) | 86 (59.3) |
| Comorbidity at ICI administration, n (%) | |||
| Myocardial infarction | 40 (5.4) | 10 (4.7) | <3 |
| Heart failure | 29 (3.9) | 5 (2.4) | <3 |
| Myocarditis | 14 (1.9) | <3 | <3 |
| Arrhythmia | 104 (14.0) | 20 (9.4) | 13 (9.0) |
| Peripheral arterial disease | 14 (1.9) | 3 (1.4) | <3 |
| Diabetes mellitus | 91 (12.2) | 22 (10.4) | 16 (11.0) |
| Hypertension | 189 (25.4) | 53 (25.0) | 39 (26.9) |
| Chronic kidney disease | 17 (2.3) | 3 (1.4) | 3 (2.1) |
| Alcohol abuse | 11 (1.5) | 12 (5.7) | 4 (2.8) |
| Chronic liver disease | 4 (0.5) | <3 | 5 (3.4) |
| Chronic obstructive pulmonary disease | 102 (13.7) | 7 (3.3) | <3 |
| Pharmacotherapy at ICI administration, n (%) | |||
| Calcium channel blockers | 114 (15.3) | 33 (15.6) | 24 (16.6) |
| Beta blockers | 150 (20.2) | 38 (17.9) | 13 (9.0) |
| Non loop diuretics | 145 (19.5) | 39 (18.4) | 38 (26.2) |
| Loop diuretics | 71 (9.6) | 12 (5.7) | 7 (4.8) |
| RAS-inhibitors | 189 (25.4) | 57 (26.9) | 41 (28.3) |
| Vitamin K antagonists | 33 (4.4) | 4 (1.9) | 3 (2.1) |
| Non vitamin K antagonists | 40 (5.4) | 3 (1.4) | 4 (2.8) |
| ADP-inhibitors | 42 (5.7) | 13 (6.1) | 8 (5.5) |
| Aspirin | 147 (19.8) | 25 (11.8) | 15 (10.3) |
| Statins | 194 (26.1) | 45 (21.2) | 23 (15.9) |
ADP, adenosine diphosphate; CTLA-4i, cytotoxic T-lymphocyte-associated protein-4 inhibitor, PD1i, programmed cell death 1 inhibitor; RAS, renin-angiotensin system.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
